A 3rd Made-in-India Vaccine - IIL of Hyderabad’s animal trials on

Human trials hopefully next year

IIL also to supply drug substance for Bharat Biotech vaccines.

NEW DELHI, May 29 (The CONNECT) – Hyderabad-based market leader in veterinary and human biologicals Indian Immunologicals Ltd (IIL) is working on a COVID -19 vaccine.

Animal trials are underway currently and the new vaccine is expected by next year for human use. This information has come out in a passing reference in a government press release.

Manufacturing over 150 products, IIL operates one of the largest plants in the world for veterinary vaccines.

Meanwhile, Bharat Biotech has signed a technical collaboration agreement with IIL for supply of drug substance required the for manufacturing Covaxin Vaccine. IIL is planning to start the production of the drug substance for Covaxin from next month and send out the first batch to Bharat Biotech limited by July, Managing Director of Indian Immunological Limited Dr K Anand Kumar said.

IIL will initially make the substance for 2-3 million doses and will be scaled up to 6-7 million per month later in the year.

Dr.Kumar said that the company is converting the Karkapatla manufacturing unit of IIL near Hyderabad into a Bio Safety Level -3 (BSL3) facility for the production of the drug substance and is also taking up construction of another block. 

Under Atmanirbhar Bharat 3.0 Mission, the Government launched COVID Suraksha to accelerate the development and production of Indigenous vaccines. Now, the Government has decided to support some public sector companies with grants and the IIL initiative is part of that.

Recent News